Multinational specialty pharmaceutical company Valeant Pharmaceuticals International has agreed to acquire Egypt-based pharmaceutical company Amoun Pharmaceutical from global private equity firms Capital Group Private Markets and The Rohatyn Group and Egypt-focused investment management company Concord International Investments for US$800 million. Amoun will serve as a platform for Valeant’s expansion in MENA’s pharmaceutical market. The transaction, which is subject to customary closing conditions, is expected to close in the third quarter of 2015.